Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where ...

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and T-DM1 (trastuzumab emtansine) which is sold under the brand name Kadcycla. Treatment of early ...

The pathologic complete response rate was 66.3% in the nab-paclitaxel arm and 57.6% in the docetaxel-carboplatin arm. The combination of nab-paclitaxel, trastuzumab, and pertuzumab may provide ...

When the mutation is present, the overproduction of HER2 proteins drives the growth of breast cancer cells. Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Get detailed information on Pertuzumab, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with ...

with negative lymph nodes have a much higher risk of recurrence relative to tumors that are HER2-negative. Treatment with Herceptin (trastuzumab) can cut this risk by half. The pattern of breast ...

This may, in turn, improve the specificity of a serum HER2 assay by identifying only that soluble HER2 variant associated with pro-oncogenic activity. However, since the trastuzumab binding site ...